Kiadis Pharma Presents ATIR and Rhitol Data and NIH Presentation on ATIR

27-Nov-2007

Kiadis Pharma announced that there will be three presentations on its products ATIR and Rhitol in poster sessions at the 2007 Annual Meeting of the American Society of hematology (ASH) December 8-11 in Atlanta, Georgia, USA. Data will be presented from the companies ongoing clinical study on ATIR by its principal investigator Dr. Denis Claude Roy, who also presents data on the functionality of Rhitol. In addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the NIH.

Dr. Denis Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "Our results indicate that the post-transplant infusion of a ATIR-PDT treated DLI is feasible, does not induce acute GVHD, and suggests a clinical benefit for patients receiving the highest DLI doses to accelerate T cell reconstitution. This PDT strategy represents an appealing alternative for older patients and those at high risk for GVHD"

"Our results demonstrate that TH9402 PDT not only eliminates activated T cells, but preserves Tregs, with the functional ability to inhibit residual alloreactive cGVHD cells. This inhibitory effect requires live effector Tregs, secretion of IL-10 and TGF-I(2) expression. With such dual effector mechanisms, photopheresis using TH9402 should translate into improved treatment efficacy and enhanced quality of life for patients with chronic GVHD"

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances